Tempus AI Q3 revenue slightly beats estimates; raises guidance
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Overview
AI-driven precision medicine firm's Q3 revenue rose 23%, slightly beating analyst expectations
Adjusted EPS for Q3 turned positive and beat analyst expectations
Company raised full-year 2026 revenue guidance and announced new collaborations with Merck, Moderna, and BMS
Outlook
Tempus raises full-year 2026 revenue guidance to $1.60-$1.605 bln
Company maintains 2026 adjusted EBITDA outlook at ~$65 mln
Result Drivers
ONCOLOGY VOLUME - Co said 32% growth in oncology test volumes drove diagnostics revenue
DATA & APPS MOMENTUM - Co said Data & Applications revenue grew 33%, with Insights up 29%
STRATEGIC COLLABORATIONS - Co cited new deals with Merck, Moderna and BMS as supporting growth
Company press release: ID:nBw7Sgzc3a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $411.54 mln | $409.35 mln (20 Analysts) |
Q3 Adjusted EPS | Beat | $0.07 | -$0.08 (16 Analysts) |
Q3 Net Loss |
| $14.85 mln |
|
Q3 Adjusted EBITDA | Beat | $25.57 mln | $18.75 mln (14 Analysts) |
Q3 Income from Operations |
| -$56.86 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Tempus AI, Inc. is $75.00, about 3.8% above its October 30 closing price of $72.22
Reuters Recommended Reads
Oct 30 - Kuaishou's Kling AI unit completes a near $3 billion funding round
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb